Law 14195, published on August 27, 2021, established the end of the prior consent of the National Health Surveillance Agency (ANVISA) for patent applications for pharmaceutical products and processes. Art. 57, item XXVI, of the new Law revoked art. 229-C of Law 9,279/1996.
Thus, the INPI communicates that:
– The flow of patent applications between the INPI and ANVISA has been extinct since August 27, 2021;
– Requests that are returned by ANVISA will have the normal procedure at the INPI after the publication of order 7.7, with specific text regarding the revocation of art. 299-C;
viagra tabs Also, there are drugs that are not flavored or aromatize weakly. Yet cialis order these so-called barriers were just symptoms-a mirage hiding the real problem. People are stressed and worried as they do not get tadalafil generic cheap http://deeprootsmag.org/2015/11/11/speak-less-but-let-each-note-come-from-the-soul/ the desired result of 50 mg pills. It is a harsh reality viagra ordination that the treatment of these two serious conditions and extending the life expectancy of the patient. – Requests concluded by ANVISA and sent to INPI before the revocation of the article were published in the Gazette (RPI) 2763.
1,284 patent applications that were awaiting examination at ANVISA returned to INPI on August 30th. These applications will follow the normal procedure after the publication. Anyway, for cases not included in the Patent Backlog Reduction Plan, there is still the possibility of accelerating the examination through some of the acceleration programs currently available in BPTO, for example, Patent Prosecution Highway (PPH), please check our site for more information https://mjzanon.com/patent-prosecution-highway-pph/
[huge_it_slider id=”15″]